Coronary interventions
Drug-coated Balloons for the Treatment of Coronary In-stent Restenosis: A Multicentre, Randomised Controlled Clinical Study November 20, 2019 | 10.4244/EIJ-D-19-00051
Showing 1-14 of 14 articles
Interventions for valvular disease
Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system December 7, 2018 | 10.4244/EIJ-D-18-00664
Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
April 20, 2018 | 10.4244/EIJ-D-17-00529
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study
November 20, 2017 | 10.4244/EIJ-D-17-00271
Interventions for valvular disease
Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients September 20, 2017 | 10.4244/EIJ-D-16-01024
Interventions for valvular disease
Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort September 20, 2017 | 10.4244/EIJ-D-16-01025
Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study
March 20, 2014 | 10.4244/EIJV9I11A216
Boston Scientific Lotus valve
September 30, 2012 | 10.4244/EIJV8SQA12